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PATIENT EDUCATION AND PROVIDER GUIDELINES FOR STEROID IN-
DUCED HYPERGLYCEMIA
Johns, A.A. Duke University Medical Center, Durham, NC
Allogeneic stem cell transplantation is an aggressive treatment op-
tion for patients with hematologic malignancies and bone marrow
failure disorders. In recent years allogeneic transplant is offered to
older patients using a reduced intensity or non-myeloablative ap-
proach. With the increasing age of our patient population there is
also an increase in co-morbidities. The incidence of diabetes in the
U.S. population is 8.3% and in people over 65 it is 26.9%. 1 We
are increasingly taking care of patients who have diabetes prior to
transplant and also patients that develop hyperglycemia after starting
steroids. Steroids increase blood glucose by stimulating gluconeo-
genesis resulting in an increase in hepatic glucose release. Glucocor-
ticoids (GC) are potent immunosuppressive agents and are first line
treatment of graft versus host disease.
Hyperglycemia may cause serious immediate problems and also
lead to long term issues. High blood sugar, levels greater than 200
mg/dl, can lead to dehydration, weight loss, and poor nutrition, in-
creased risk of infection due to functional decline of neutrophils,
electrolyte imbalance and acidosis.2 Long term issues include
changes in vision, kidney and vascular diseases.
Themajority of patients who develop hyperglycemia during trans-
plant with not need long term treatment once the steroids are
stopped. Patients with pre-existing diabetes will need adjustment
of the hypoglycemic agents during steroid treatment. We developed
patient teaching guidelines and staff treatment guidelines for manag-
ing hyperglycemia in the transplant setting. Standardized teaching
tools for patients in both English and Spanish were developed.
Guidelines for nurses and providers were developed to provide
a standard approach to management of hyperglycemia.530
EXPERIENCE WITH A SIMPLE INTERVENTION TO DECREASE CLOSTRID-
IUM DIFFICILE INFECTIONS (CDIs) ON A BONE MARROW TRANSPLANT
UNIT
Flesch, L., Connelly, B., Hayward, M., Cloughessy, M., Mott, B.,
Horgan, K., Brown, R., Ward, T., Davies, S. CCHMC, Cincinnati, OH
Cincinnati Children’s Hospital Medical Center’s Bone Marrow
Transplant Unit is a 24 bed critical care environment that cares for
highly complex immune compromised patient population with un-
derlying oncologic, immunologic, marrow failure or metabolic dis-
orders.
Prospective surveillance for health care associated infections
(HAI’s) is performed through the Infection Control Program and re-
viewed on a semi-annual basis with unit leadership and staff. Daily
laboratory alerts for C. difficile toxin are followed up by infection
control staff to assure timely institution of contact precautions.
For CDI patients, hand washing is specified as the hand hygiene
practice to be used at the end of care and before exiting a patient’s
room.
During 2009, surveillance identified an increase in CDI cases on
the BMT unit well above the previous baseline. Isolation and envi-
ronmental cleaning practices on the unit were reviewed. Bleach
was implemented for discharge cleaning of all CDI patient rooms
and patient bathrooms. Hand washing on patient room exit was re-
inforced with education and signs. Staff began implementing initia-
tives to de-clutter the unit and facilitate environmental cleaning.
CDIs on the unit continued to increase. Following the semi-annual
data review, in September of 2010, alcohol gels were removed from
all patient rooms on the unit and a ‘‘gel in, wash out’’ initiative was
adopted. The number of CDI cases has fallen and time between
CDIs has increased. There have been no new CDIs recognized on
the unit in 8 of the last 12 months.
While there were many improvement initiatives focused on the
environment, we believe the greatest impact for the decrease inCDIs came from the simple maneuver of forcing hand washing
with soap and water before exiting a patient room. This simple
change adds to patient safety by removing potential pathogens
that may not be removed or killed by hand gel sanitizing
products.531
INCIDENCE OF ADRENAL INSUFFICIENCY IN CHILDREN WITH SANFI-
LIPPO SYNDROME TYPE A FOLLOWING UUCB TRANSPLANT – A RETRO-
SPECTIVE STUDY
Moffet, J.1, Parikh, S.1, Driscoll, T.1, Szabolcs, P.2, Kurtzberg, J.1 1Duke
University, Durham, NC; 2Children’s Hospital of Pittsburgh, Pittsburgh,
PA
Background: We observed an unusually high incidence of adrenal
insufficiency in children with Sanfilippo Syndrome Type A
(MPSIIIA) after unrelated donor umbilical cord blood transplanta-
tion. Many of these children experienced repeated hospitalizations
and emergency department visits due to adrenal crisis.
Patients and Methods:We conducted a retrospective chart review
to evaluate the incidence and severity of adrenal complications fol-
lowing unrelated umbilical cord blood transplant in children with
MPS IIIA. Seventeen consecutive children with MPS IIIA were
transplanted between 2001 and 2010; 10 patients were male and 7
were female. Median age at transplant was 2.88 years (1.05-4.96).
All children received an unrelated umbilical cord blood transplant
following myeloablative conditioning with busulfan, cyclophospha-
mide and ATG. 1 child was not evaluable due to death prior to day
+100. Eight children received Cyclosporine and low dose steroids
as GVHD prophylaxis and 8 children received Cyclosporine and
Mycophenolate. Of the 8 children who received Cyclosporine and
Mycophenolate, 7 required methylprednisolone post transplant (6
for engraftment syndrome, 1 for pulmonary edema). Cortisol defi-
ciency was defined as an AM fasting cortisol of\5mcg/dl on or after
day +100.
Results: Thirteen of 16 (81%) children transplanted for MPSIIIA
became cortisol deficient post transplant. Six of 8 (75%) children
who received CYA+low dose steroid became adrenally insufficient.
Seven of 8 (87%) children who received CYA+MMF became adre-
nally insufficient. Of the 8 childrenwho receivedCYA+MMF, 7 chil-
dren required methylprednisolone (2mg/kg) for engraftment
syndrome (n 5 6) or pulmonary edema (n 5 1). Six of 7 (86%) chil-
dren who received CYA+MMF and additional steroids became adre-
nally insufficient. Seven of 16 (44%) children developed chronic
GVHD and 6 of 7 (86%) of the children who developed cGHVD
were also adrenally insufficient. Nine of 16 children (56%) did not
develop cGVHD and 7 of 9 (78%) children with no evidence of
cGVHD were adrenally insufficient.
Conclusions: Adrenal insufficiency developed in the majority of pa-
tients with MPS IIIA transplanted with umbilical cord blood after
myeloablative chemotherapy. The presence of chronic GVHD and
type of prophylactic GVHD regimen did not appear to be related
to the incidence of adrenal insufficiency in these children. The cause
of this complication is currently unknown but should be the subject
of future investigations.
Table 1. Patient Characteristics
Cortisol Non-cortisol
Deficient n 5 13 deficient n 5 3Male 8 1
Female 5 2
GVHD Prophylaxis CYA+low dose
steroids6 2GVHD Prophylaxis CYA+MMF 7 1
Additional steroids in the MMF group 6 1
Chronic GVHD present 6 1
No cGVHD 7 2
